A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial
- 30 April 1994
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 23 (5), 993-1003
- https://doi.org/10.1016/0735-1097(94)90581-9
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy.Circulation Research, 1992
- Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.Circulation, 1991
- Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival?Journal of the American College of Cardiology, 1991
- Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.Circulation, 1990
- Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.Circulation, 1990
- The Structure of a Complex of Recombinant Hirudin and Human α-ThrombinScience, 1990
- Enhancing thrombolytic efficacy by means of “front-loaded” administration of tissue plasminogen activatorJournal of the American College of Cardiology, 1989
- Biology of Recombinant Hirudin (CGP 39393): A New Prospect in the Treatment of ThrombosisSeminars in Thrombosis and Hemostasis, 1989
- Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.Circulation, 1989
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985